Drugs / REGN2176-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02061865 | Feb → Dec 2014 | wet macular degeneration | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN2176-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02061865 ↗ |
| Route | Intravitreal | “intravitreal (IVT) REGN2176-3” NCT02061865 ↗ |